PDL BioPharma Stock Price, News & Analysis (NASDAQ:PDLI)

$2.45 -0.02 (-0.81 %)
(As of 02/20/2018 04:00 PM ET)
Previous Close$2.45
Today's Range$2.43 - $2.50
52-Week Range$1.96 - $3.55
Volume1.42 million shs
Average Volume1.24 million shs
Market Capitalization$378.13 million
P/E Ratio4.90
Dividend YieldN/A
Beta0.48

About PDL BioPharma (NASDAQ:PDLI)

PDL BioPharma logoPDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.

Receive PDLI News and Ratings via Email

Sign-up to receive the latest news and ratings for PDLI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:PDLI
CUSIP69329Y10
Phone+1-775-8328500

Debt

Debt-to-Equity Ratio0.14%
Current Ratio3.16%
Quick Ratio3.10%

Price-To-Earnings

Trailing P/E Ratio4.9
Forward P/E Ratio4.08
P/E GrowthN/A

Sales & Book Value

Annual Sales$244.30 million
Price / Sales1.55
Cash Flow$0.41 per share
Price / Cash5.96
Book Value$4.56 per share
Price / Book0.54

Profitability

Trailing EPS$0.50
Net Income$63.60 million
Net Margins24.51%
Return on Equity9.20%
Return on Assets5.84%

Miscellaneous

Employees11
Outstanding Shares154,340,000

PDL BioPharma (NASDAQ:PDLI) Frequently Asked Questions

What is PDL BioPharma's stock symbol?

PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."

How will PDL BioPharma's stock buyback program work?

PDL BioPharma announced that its board has authorized a share buyback plan on Monday, September 25th 2017, which allows the company to buyback $25,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Shares buyback plans are often a sign that the company's board of directors believes its stock is undervalued.

How were PDL BioPharma's earnings last quarter?

PDL BioPharma Inc (NASDAQ:PDLI) announced its quarterly earnings data on Thursday, November, 2nd. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.13 by $0.01. The biotechnology company earned $62.75 million during the quarter, compared to analyst estimates of $61.86 million. PDL BioPharma had a return on equity of 9.20% and a net margin of 24.51%. The firm's quarterly revenue was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.08 earnings per share. View PDL BioPharma's Earnings History.

When will PDL BioPharma make its next earnings announcement?

PDL BioPharma is scheduled to release their next quarterly earnings announcement on Wednesday, February, 21st 2018. View Earnings Estimates for PDL BioPharma.

Where is PDL BioPharma's stock going? Where will PDL BioPharma's stock price be in 2018?

2 brokers have issued 1 year price targets for PDL BioPharma's stock. Their forecasts range from $3.00 to $4.00. On average, they anticipate PDL BioPharma's share price to reach $3.50 in the next year. View Analyst Ratings for PDL BioPharma.

What are Wall Street analysts saying about PDL BioPharma stock?

Here are some recent quotes from research analysts about PDL BioPharma stock:

  • 1. According to Zacks Investment Research, "PDL BioPharma is focused on acquiring and managing income-generating assets. It has royalty agreements with several companies, whereby it receives royalties on sales of their products. We are positive on the company’s recent strategic shift, wherein, it is making equity investments in product-focused companies. The company’s investment on Noden Pharma, focused on acquiring and optimizing established medicines, is also encouraging. Its shares have outperformed the industry so far this year. However, the company is heavily dependent on its partners for royalty revenues, which is not a risk-free strategy. We are also concerned about PDL BioPharma’s revenue stream in the future as its growth prospects rely on the timing and ability to acquire new income-generating assets for recurring revenues. Estimates have remained stable ahead of Q4 earnings. The company has a mixed record of earnings surprises in the recent quarters." (1/8/2018)
  • 2. Cowen Inc analysts commented, "PDL reported an in-line Q1 with both total revenue ($45MM vs $43MM) and EPS." (5/3/2017)

Who are some of PDL BioPharma's key competitors?

Who are PDL BioPharma's key executives?

PDL BioPharma's management team includes the folowing people:

  • Dominique Monnet, President (Age 59)
  • John Peter McLaughlin, Chief Executive Officer, Director (Age 65)
  • Peter S. Garcia, Chief Financial Officer, Vice President (Age 55)
  • Steffen Pietzke CPA, Chief Accounting Officer, Vice President - Finance (Age 44)
  • Christopher Lewis Stone J.D., Vice President, General Counsel, Secretary (Age 52)
  • Harold E. Selick Ph.D., Lead Independent Director (Age 62)
  • Paul R. Edick, Independent Director (Age 62)
  • David W. Gryska, Independent Director (Age 61)
  • Jody S. Lindell, Independent Director (Age 66)
  • Samuel R. Saks M.D., Independent Director (Age 62)

Who owns PDL BioPharma stock?

PDL BioPharma's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.53%), Renaissance Technologies LLC (6.66%), Mackenzie Financial Corp (3.14%), Schwab Charles Investment Management Inc. (2.03%), Geode Capital Management LLC (1.37%) and Kestrel Investment Management Corp (1.09%). View Institutional Ownership Trends for PDL BioPharma.

Who sold PDL BioPharma stock? Who is selling PDL BioPharma stock?

PDL BioPharma's stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Fuller & Thaler Asset Management Inc., Two Sigma Investments LP, TIAA CREF Investment Management LLC, Mackenzie Financial Corp, Robeco Institutional Asset Management B.V. and Alps Advisors Inc.. View Insider Buying and Selling for PDL BioPharma.

Who bought PDL BioPharma stock? Who is buying PDL BioPharma stock?

PDL BioPharma's stock was acquired by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, BlackRock Inc., Bank of Montreal Can, Chicago Equity Partners LLC, Mckinley Capital Management LLC Delaware, AXA, KBC Group NV and California Public Employees Retirement System. View Insider Buying and Selling for PDL BioPharma.

How do I buy PDL BioPharma stock?

Shares of PDL BioPharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PDL BioPharma's stock price today?

One share of PDL BioPharma stock can currently be purchased for approximately $2.45.

How big of a company is PDL BioPharma?

PDL BioPharma has a market capitalization of $378.13 million and generates $244.30 million in revenue each year. The biotechnology company earns $63.60 million in net income (profit) each year or $0.50 on an earnings per share basis. PDL BioPharma employs 11 workers across the globe.

How can I contact PDL BioPharma?

PDL BioPharma's mailing address is 932 Southwood Blvd, INCLINE VILLAGE, NV 89451, United States. The biotechnology company can be reached via phone at +1-775-8328500 or via email at [email protected]


MarketBeat Community Rating for PDL BioPharma (PDLI)

Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  86 (Vote Outperform)
Underperform Votes:  190 (Vote Underperform)
Total Votes:  276
MarketBeat's community ratings are surveys of what our community members think about PDL BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

PDL BioPharma (NASDAQ:PDLI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.502.50
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.50$3.50$3.50$4.00
Price Target Upside: 18.24% upside18.24% upside18.24% upside51.52% upside

PDL BioPharma (NASDAQ:PDLI) Consensus Price Target History

Price Target History for PDL BioPharma (NASDAQ:PDLI)

PDL BioPharma (NASDAQ:PDLI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/27/2017CowenReiterated RatingHold$3.00N/AView Rating Details
8/10/2017Piper Jaffray CompaniesReiterated RatingBuy$4.00MediumView Rating Details
2/23/2016Royal Bank of CanadaLower Price TargetSector Perform$5.00 -> $4.00N/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

PDL BioPharma (NASDAQ:PDLI) Earnings History and Estimates Chart

Earnings by Quarter for PDL BioPharma (NASDAQ:PDLI)

PDL BioPharma (NASDAQ PDLI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2018$0.11N/AView Earnings Details
11/2/2017Q3 2017$0.13$0.14$61.86 million$62.75 millionViewN/AView Earnings Details
8/3/2017Q2 2017$0.09$0.26$56.30 million$143.80 millionViewListenView Earnings Details
5/3/2017Q1 2017$0.05$0.08$45.44 millionViewListenView Earnings Details
11/3/2016Q316$0.08$0.08$50.69 million$53.60 millionViewN/AView Earnings Details
8/4/2016Q216$0.08$0.09$33.46 million$21.00 millionViewN/AView Earnings Details
5/4/2016Q116$0.50$0.52$142.05 million$103.10 millionViewN/AView Earnings Details
2/22/2016Q415$0.54$0.61$149.20 million$178.10 millionViewListenView Earnings Details
11/4/2015Q315$0.61$0.42$164.80 million$124.60 millionViewN/AView Earnings Details
8/5/2015Q215$0.52$0.47$137.75 million$138.10 millionViewN/AView Earnings Details
5/6/2015Q115$0.52$0.50$140.80 million$149.71 millionViewN/AView Earnings Details
2/23/2015Q414$0.57$0.32$158.15 million$117.10 millionViewListenView Earnings Details
11/10/2014Q314$0.56$0.61$165.10 million$164.60 millionViewN/AView Earnings Details
8/18/2014Q214$0.46$0.52$134.07 million$162.80 millionViewListenView Earnings Details
5/12/2014Q114$0.45$0.44$130.93 million$139.70 millionViewN/AView Earnings Details
3/3/2014Q413$0.43$0.39$115.22 million$110.10 millionViewN/AView Earnings Details
11/6/2013Q313$0.37$0.36$97.09 million$97.30 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.54$0.62$138.20 million$143.60 millionViewN/AView Earnings Details
5/9/2013Q1 2013$0.35$0.36$91.69 million$91.80 millionViewN/AView Earnings Details
3/1/2013Q4 2012$0.31$0.34$86.08 million$86.10 millionViewN/AView Earnings Details
11/5/2012Q312$0.33$0.32$85.03 million$85.20 millionViewN/AView Earnings Details
8/2/2012$0.44$0.52ViewN/AView Earnings Details
5/3/2012$0.27$0.29ViewN/AView Earnings Details
2/23/2012$0.28$0.24ViewN/AView Earnings Details
11/9/2011$0.27$0.28ViewN/AView Earnings Details
7/27/2011$0.39$0.39ViewN/AView Earnings Details
4/27/2011$0.24$0.25ViewN/AView Earnings Details
2/28/2011$0.21$0.20ViewN/AView Earnings Details
11/10/2010Q3 2010$0.25$0.25ViewN/AView Earnings Details
7/28/2010Q2 2010$0.38$0.38ViewN/AView Earnings Details
4/29/2010Q1 2010$0.23$0.15ViewN/AView Earnings Details
3/2/2010Q4 2009$0.19$0.17ViewN/AView Earnings Details
10/28/2009Q3 2009$0.26$0.28ViewN/AView Earnings Details
7/30/2009Q2 2009$0.42$0.45ViewN/AView Earnings Details
5/7/2009Q1 2009$0.24$0.23ViewN/AView Earnings Details
3/2/2009Q4 2008$0.06$0.34ViewN/AView Earnings Details
11/6/2008Q3 2008$0.24$0.08ViewN/AView Earnings Details
8/11/2008Q2 2008$0.21$0.36ViewN/AView Earnings Details
5/8/2008Q1 2008($0.01)($0.08)ViewN/AView Earnings Details
3/4/2008Q4 2007$0.15($0.01)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

PDL BioPharma (NASDAQ:PDLI) Earnings Estimates

Current Year EPS Consensus Estimate: $0.6 EPS
Next Year EPS Consensus Estimate: $0.1 EPS

Dividends

PDL BioPharma (NASDAQ:PDLI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/4/2016quarterly$0.056.25%6/2/20166/6/20166/13/2016
2/1/2016quarterly$0.057.27%3/2/20163/4/20163/11/2016
2/2/2015quarterly$0.158.22%6/1/20166/5/20166/12/2016
1/30/2015quarterly$0.158.23%6/3/20156/5/20156/12/2015
1/30/2015quarterly$0.158.23%3/3/20153/5/20153/12/2015
1/30/2015quarterly$0.158.23%12/2/201512/4/201512/11/2015
1/30/2015quarterly$0.158.23%9/2/20159/4/20159/11/2015
1/31/2014quarterly$0.156.59%9/3/20149/5/20149/12/2014
1/31/2014quarterly$0.156.59%3/3/20143/5/20143/12/2014
1/31/2014quarterly$0.156.59%12/3/201412/5/201412/12/2014
1/31/2014quarterly$0.156.59%6/3/20146/5/20146/12/2014
1/31/2013quarterly$0.158.72%12/3/201312/5/201312/12/2013
1/31/2013quarterly$0.158.72%6/3/20136/5/20136/12/2013
1/31/2013quarterly$0.158.72%9/3/20139/5/20139/12/2013
1/30/2013quarterly$0.158.72%3/1/20133/5/20133/12/2013
(Data available from 1/1/2013 forward)

Insider Trades

PDL BioPharma (NASDAQ PDLI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.20%
Institutional Ownership Percentage: 90.52%
Insider Trades by Quarter for PDL BioPharma (NASDAQ:PDLI)
Institutional Ownership by Quarter for PDL BioPharma (NASDAQ:PDLI)

PDL BioPharma (NASDAQ PDLI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/24/2017Peter S GarciaVPBuy25,000$1.98$49,500.00452,492View SEC Filing  
8/9/2016Peter S GarciaVPBuy10,000$3.00$30,000.00232,092View SEC Filing  
12/15/2015Peter S. GarciaCFOBuy5,000$3.64$18,200.00126,041View SEC Filing  
12/14/2015Peter S. GarciaCFOBuy10,000$3.42$34,200.00126,041View SEC Filing  
12/7/2015Steffen PietzkeCAOBuy20,590$3.64$74,947.60View SEC Filing  
8/14/2015Peter S GarciaCFOBuy20,000$5.83$116,600.00View SEC Filing  
11/26/2014Harold E SelickDirectorBuy6,000$8.08$48,480.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

PDL BioPharma (NASDAQ PDLI) News Headlines

Source:
DateHeadline
PDL BioPharma (PDLI) Terminates Interest in Pursuing Acquisition of Neos (NEOS)PDL BioPharma (PDLI) Terminates Interest in Pursuing Acquisition of Neos (NEOS)
www.streetinsider.com - February 20 at 8:39 AM
PDL BioPharma Terminates Interest in Pursuing Acquisition of NeosPDL BioPharma Terminates Interest in Pursuing Acquisition of Neos
finance.yahoo.com - February 20 at 8:39 AM
PDL BioPharma (PDLI) Downgraded by BidaskClub to Strong SellPDL BioPharma (PDLI) Downgraded by BidaskClub to Strong Sell
www.americanbankingnews.com - February 19 at 4:02 PM
 Brokerages Expect PDL BioPharma Inc (PDLI) Will Post Earnings of $0.03 Per Share Brokerages Expect PDL BioPharma Inc (PDLI) Will Post Earnings of $0.03 Per Share
www.americanbankingnews.com - February 15 at 8:58 AM
PDLI Feb 2018 2.000 callPDLI Feb 2018 2.000 call
finance.yahoo.com - February 15 at 8:13 AM
PDL BioPharma (PDLI) to Release Earnings on WednesdayPDL BioPharma (PDLI) to Release Earnings on Wednesday
www.americanbankingnews.com - February 14 at 2:56 AM
What Are the Best Healthcare Stocks to Buy? Here Are a Top AI System's 5 FavoritesWhat Are the Best Healthcare Stocks to Buy? Here Are a Top AI System's 5 Favorites
finance.yahoo.com - February 8 at 8:30 AM
PDL BioPharma Inc (PDLI) Receives Average Recommendation of "Hold" from BrokeragesPDL BioPharma Inc (PDLI) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 27 at 11:56 AM
PDL BioPharma (PDLI) Stock Rating Lowered by Zacks Investment ResearchPDL BioPharma (PDLI) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 8 at 12:38 PM
PDL BioPharma (PDLI) Downgraded to "Sell" at BidaskClubPDL BioPharma (PDLI) Downgraded to "Sell" at BidaskClub
www.americanbankingnews.com - January 6 at 5:06 PM
PDL BioPharma Inc (PDLI) Receives Consensus Rating of "Buy" from BrokeragesPDL BioPharma Inc (PDLI) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 2 at 12:22 PM
 Analysts Expect PDL BioPharma Inc (PDLI) to Post $0.11 Earnings Per Share Analysts Expect PDL BioPharma Inc (PDLI) to Post $0.11 Earnings Per Share
www.americanbankingnews.com - December 26 at 9:21 PM
PDL BioPharma Inc (PDLI) Expected to Post Earnings of $0.11 Per SharePDL BioPharma Inc (PDLI) Expected to Post Earnings of $0.11 Per Share
www.americanbankingnews.com - December 26 at 9:21 PM
ETFs with exposure to PDL BioPharma, Inc. : December 25, 2017ETFs with exposure to PDL BioPharma, Inc. : December 25, 2017
finance.yahoo.com - December 25 at 6:06 PM
PDL BioPharma, Inc. (PDLI) Jumps: Stock Rises 8.2% - NasdaqPDL BioPharma, Inc. (PDLI) Jumps: Stock Rises 8.2% - Nasdaq
www.nasdaq.com - December 21 at 4:35 PM
PDL BioPharma, Inc. (PDLI) Jumps: Stock Rises 8.2%PDL BioPharma, Inc. (PDLI) Jumps: Stock Rises 8.2%
finance.yahoo.com - December 18 at 10:48 AM
ETFs with exposure to PDL BioPharma, Inc. : December 13, 2017ETFs with exposure to PDL BioPharma, Inc. : December 13, 2017
finance.yahoo.com - December 13 at 4:42 PM
PDL BioPharma, Inc. :PDLI-US: Earnings Analysis: Q3, 2017 By the Numbers : December 12, 2017PDL BioPharma, Inc. :PDLI-US: Earnings Analysis: Q3, 2017 By the Numbers : December 12, 2017
finance.yahoo.com - December 12 at 10:51 AM
Zacks: Brokerages Anticipate PDL BioPharma, Inc. (PDLI) to Post $0.11 EPSZacks: Brokerages Anticipate PDL BioPharma, Inc. (PDLI) to Post $0.11 EPS
www.americanbankingnews.com - December 9 at 8:04 AM
PDL BioPharma, Inc. (PDLI) Receives Average Rating of "Buy" from AnalystsPDL BioPharma, Inc. (PDLI) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - December 8 at 11:42 AM
Short Interest in PDL BioPharma, Inc. (PDLI) Declines By 6.3%Short Interest in PDL BioPharma, Inc. (PDLI) Declines By 6.3%
www.americanbankingnews.com - November 28 at 3:02 AM
PDL BioPharma, Inc. (PDLI) Upgraded at ValuEnginePDL BioPharma, Inc. (PDLI) Upgraded at ValuEngine
www.americanbankingnews.com - November 25 at 6:06 AM
$0.11 Earnings Per Share Expected for PDL BioPharma, Inc. (PDLI) This Quarter$0.11 Earnings Per Share Expected for PDL BioPharma, Inc. (PDLI) This Quarter
www.americanbankingnews.com - November 21 at 7:42 AM
Noden Pharma Announces FDA Approval of Tekturna®(aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and OlderNoden Pharma Announces FDA Approval of Tekturna®(aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older
finance.yahoo.com - November 18 at 10:48 AM
PDL BioPharma, Inc. (PDLI) Given Average Recommendation of "Buy" by AnalystsPDL BioPharma, Inc. (PDLI) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 13 at 12:34 PM
PDL BioPharma to Present at Two Upcoming Investor ConferencesPDL BioPharma to Present at Two Upcoming Investor Conferences
finance.yahoo.com - November 9 at 11:13 AM
Factors of Influence in 2018, Key Indicators and Opportunity within Tegna, Inpixon, Honeywell International, Nektar, PDL Biopharma, and Innoviva – New Research Emphasizes Economic GrowthFactors of Influence in 2018, Key Indicators and Opportunity within Tegna, Inpixon, Honeywell International, Nektar, PDL Biopharma, and Innoviva – New Research Emphasizes Economic Growth
finance.yahoo.com - November 9 at 11:13 AM
EARNINGS SUMMARY: Details of PDL BioPharma Inc. Q3 Earnings ReportEARNINGS SUMMARY: Details of PDL BioPharma Inc. Q3 Earnings Report
www.rttnews.com - November 4 at 4:30 PM
PDL BioPharmas (PDLI) CEO John McLaughlin on Q3 2017 Results - Earnings Call TranscriptPDL BioPharma's (PDLI) CEO John McLaughlin on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 4 at 4:30 PM
PDL BioPharma, Inc. to Host Earnings CallPDL BioPharma, Inc. to Host Earnings Call
finance.yahoo.com - November 4 at 4:30 PM
PDL BioPharma Announces Third Quarter 2017 Financial ResultsPDL BioPharma Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 4 at 4:30 PM
PDL BioPharma posts 3Q profitPDL BioPharma posts 3Q profit
finance.yahoo.com - November 4 at 4:30 PM
Edited Transcript of PDLI earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of PDLI earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 4 at 4:30 PM
PDL BioPharma (PDLI) Q3 Earnings Beat, Revenues Rise Y/Y - NasdaqPDL BioPharma (PDLI) Q3 Earnings Beat, Revenues Rise Y/Y - Nasdaq
www.nasdaq.com - November 4 at 8:43 AM
PDL BioPharma, Inc. (PDLI) Posts Quarterly  Earnings Results, Beats Expectations By $0.01 EPSPDL BioPharma, Inc. (PDLI) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - November 3 at 6:24 PM
Why Neos Therapeutics Is Holding Out Against PDL BioPharma - 24/7 Wall St.Why Neos Therapeutics Is Holding Out Against PDL BioPharma - 24/7 Wall St.
247wallst.com - October 31 at 7:45 AM
PDL BioPharma, Inc. – Value Analysis (NASDAQ:PDLI) : October 27, 2017PDL BioPharma, Inc. – Value Analysis (NASDAQ:PDLI) : October 27, 2017
finance.yahoo.com - October 28 at 12:43 PM
PDL BioPharma makes unsolicited bid to buy Neos Therapeutics for a 40% premium - MarketWatchPDL BioPharma makes unsolicited bid to buy Neos Therapeutics for a 40% premium - MarketWatch
www.marketwatch.com - October 27 at 9:28 AM
PDL BioPharma, Inc. (PDLI) Set to Announce Earnings on WednesdayPDL BioPharma, Inc. (PDLI) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - October 25 at 8:02 AM
ETFs with exposure to PDL BioPharma, Inc. : October 20, 2017ETFs with exposure to PDL BioPharma, Inc. : October 20, 2017
finance.yahoo.com - October 21 at 8:05 AM
PDL BioPharma, Inc. (PDLI) Expected to Announce Earnings of $0.13 Per SharePDL BioPharma, Inc. (PDLI) Expected to Announce Earnings of $0.13 Per Share
www.americanbankingnews.com - October 12 at 10:30 PM
Amgen Label Expansion Application for Prolia Accepted by FDA - NasdaqAmgen Label Expansion Application for Prolia Accepted by FDA - Nasdaq
www.nasdaq.com - October 11 at 6:30 AM
ETFs with exposure to PDL BioPharma, Inc. : October 9, 2017ETFs with exposure to PDL BioPharma, Inc. : October 9, 2017
finance.yahoo.com - October 9 at 11:49 PM
PDL BioPharma, Inc. :PDLI-US: Earnings Analysis: Q2, 2017 By the Numbers : September 27, 2017PDL BioPharma, Inc. :PDLI-US: Earnings Analysis: Q2, 2017 By the Numbers : September 27, 2017
finance.yahoo.com - October 3 at 10:31 AM
ETFs with exposure to PDL BioPharma, Inc. : September 28, 2017ETFs with exposure to PDL BioPharma, Inc. : September 28, 2017
finance.yahoo.com - October 3 at 10:31 AM
Seattle Genetics (SGEN) in Focus: Stock Moves 7.9% HigherSeattle Genetics (SGEN) in Focus: Stock Moves 7.9% Higher
finance.yahoo.com - October 3 at 10:31 AM
PDL BioPharma, Inc. (PDLI) Sees Significant Growth in Short InterestPDL BioPharma, Inc. (PDLI) Sees Significant Growth in Short Interest
www.americanbankingnews.com - September 28 at 3:18 AM
PDL BioPharma (PDLI) Presents At Cantor Fitzgerald Global Healthcare Conference - SlideshowPDL BioPharma (PDLI) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 27 at 6:08 PM
PDL BioPharma (PDLI) Reports $25M Share Buyback ProgramPDL BioPharma (PDLI) Reports $25M Share Buyback Program
www.streetinsider.com - September 25 at 5:01 PM
Stock Buyback Plan Declared by PDL BioPharma (PDLI) Board of Directors Stock Buyback Plan Declared by PDL BioPharma (PDLI) Board of Directors
www.americanbankingnews.com - September 25 at 11:24 AM

SEC Filings

PDL BioPharma (NASDAQ:PDLI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

PDL BioPharma (NASDAQ:PDLI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

PDL BioPharma (NASDAQ PDLI) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.